| Chapter title |
Evaluation of histone deacetylase inhibitors as therapeutics for neurodegenerative diseases.
|
|---|---|
| Chapter number | 32 |
| Book title |
Neurodegeneration
|
| Published in |
Methods in molecular biology, January 2011
|
| DOI | 10.1007/978-1-61779-328-8_32 |
| Pubmed ID | |
| Book ISBNs |
978-1-61779-327-1, 978-1-61779-328-8
|
| Authors |
Elisabetta Soragni, Chunping Xu, Andrew Cooper, Heather L. Plasterer, James R. Rusche, Joel M. Gottesfeld, Soragni, Elisabetta, Xu, Chunping, Cooper, Andrew, Plasterer, Heather L., Rusche, James R., Gottesfeld, Joel M. |
| Abstract |
Various neurodegenerative diseases are associated with aberrant gene expression. We recently identified a novel class of pimelic o-aminobenzamide histone deacetylase (HDAC) inhibitors that show promise as therapeutics in the neurodegenerative diseases Friedreich's ataxia (FRDA) and Huntington's disease (HD). Here, we describe the various techniques used in our laboratories to dissect mechanisms of gene silencing in FRDA and HD, and to test our HDAC inhibitors for their ability to reverse changes in gene expression in cellular models. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Unknown | 37 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 12 | 32% |
| Professor > Associate Professor | 4 | 11% |
| Student > Bachelor | 3 | 8% |
| Student > Postgraduate | 3 | 8% |
| Student > Master | 3 | 8% |
| Other | 6 | 16% |
| Unknown | 7 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 9 | 24% |
| Biochemistry, Genetics and Molecular Biology | 7 | 18% |
| Neuroscience | 4 | 11% |
| Chemistry | 3 | 8% |
| Nursing and Health Professions | 2 | 5% |
| Other | 5 | 13% |
| Unknown | 8 | 21% |